Last $0.51 USD
Change Today -0.0211 / -3.98%
Volume 808.3K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 3:57 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Announces Positive Interim Data from Phase II Melanoma Study

OncoSec Medical Inc. has announced positive interim data from a Phase II study of ImmunoPulse in patients with advanced melanoma. Data from the multicenter, open-label, single-arm study confirmed the safety of OncoSec's lead product candidate, ImmunoPulse, which delivers the anti-tumor agent pIL-12 directly into the tumor via in-vivo electroporation (EP), with no treatment-related serious adverse events or deaths having been reported. Regression of treated and non-treated tumors suggests successful induction of systemic anti-tumor response. To date, 30 patients have been enrolled and have received at least one cycle of treatment. At the time of this interim analysis, 28 patients were evaluable for objective response rate (ORR) at 24-week primary time point.

OncoSec Medical Inc. Appoints Dr. Soldano Ferrone to Scientific Advisory Board

OncoSec Medical Inc. has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.

OncoSec Medical Incorporated Presents at BIO International Convention, Jun-25-2014 02:45 PM

OncoSec Medical Incorporated Presents at BIO International Convention, Jun-25-2014 02:45 PM. Venue: San Diego Convention Center, San Diego, California, United States.

OncoSec Medical Inc. Announces Earnings Results for the Nine Months Ended April 30, 2014

OncoSec Medical Inc. announced earnings results for the nine months ended April 30, 2014. For the period, the company reported a net loss of $8.5 million, or $0.05 per share, compared to a net loss of $5.4 million, or $0.05 per share, for the same period last year. There were no revenues for the nine months ended April 30, 2014 or April 30, 2013.

OncoSec Medical Incorporated, Annual General Meeting, Jul 18, 2014

OncoSec Medical Incorporated, Annual General Meeting, Jul 18, 2014., at 09:00 Pacific Standard Time. Location: Principal Executive Offices. Agenda: To elect four directors to Board of Directors to serve for a term of one year or until their successors are duly elected and qualified; to ratify the appointment of Mayer Hoffman McCann P.C. as the company's independent registered public accounting firm for the fiscal year ending July 31, 2014; to approve the amendment and restatement of the company's 2011 Stock Incentive Plan to, among other things, authorize the issuance of an additional 16,000,000 shares of common stock under the 2011 Plan; and to transact other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.51 USD -0.0211

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.